Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage

Diener, H.-C., Stanford, S., Abdul-Rahim, A. , Christensen, L., Hougaard, K. D., Bakhai, A., Veltkamp, R. and Worthmann, H. (2014) Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Review of Neurotherapeutics, 14(9), pp. 1019-1028. (doi: 10.1586/14737175.2014.945435)

Full text not currently available from Enlighten.

Abstract

Patients with atrial fibrillation have an increased risk of ischemic stroke that can be dramatically lowered by treatment with anticoagulants. The annual rate of major bleeds with warfarin averages about 2%. The rates of intracerebral and intracranial bleeds are significantly reduced with the use of the novel direct oral anticoagulants (DOACs) compared with warfarin. Treatment of anticoagulation-related intracerebral hemorrhage is based on the results of case series and small trials. Resumption of anticoagulation in patients with atrial fibrillation who had an intracerebral bleed depends on the etiology and location of the bleeding and the absolute rate of stroke in the absence of anticoagulation.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Abdul-Rahim, Dr Azmil
Authors: Diener, H.-C., Stanford, S., Abdul-Rahim, A., Christensen, L., Hougaard, K. D., Bakhai, A., Veltkamp, R., and Worthmann, H.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Expert Review of Neurotherapeutics
Publisher:Expert Reviews Ltd.
ISSN:1473-7175
ISSN (Online):1744-8360

University Staff: Request a correction | Enlighten Editors: Update this record